ARCHIVES

CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

DCT Board Ok’s PA, BRM Contract Concepts

October 30, 1992

BRCA2 Carriers Reduced BC Risk By Prophylactic Surgery

June 30, 2006

NCI’s $65 Million to NTP Will Be Controversial, Untouchable; Spectre Of Another Backlog Looms

February 8, 1980

NCI To Spend About $150 Mil. On Cancers That Affect Only Women

April 26, 1991

Montana Drug Salesman Pleads Guilty to Selling Counterfeit Avastin

July 25, 2013